默克公司皮下注射Keytruda获日本批准（MRK:NYSE）
· seekingalpha.com
默克公司皮下注射KEYTRUDA QLEX/KEYJECT在日本获批，覆盖Keytruda所有适应症；基于3期数据，给药时间缩短至1-2分钟。
Merck (MRK) has secured Japanese regulatory approval for KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) for subcutaneous injection, covering all ...